Russell W. Jenkins

Oncology · 2006–2018

A researcher in the Science corpus: 5 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Russell W. Jenkins trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll
  2. Ton N. Schumacher
  3. S. Spranger
  4. T. Gajewski
  5. M. Smyth
  6. J. Joyce
  7. J. Harty

Papers from Russell W. Jenkins's perspective

Ordered by how strongly the researchers Russell W. Jenkins trusts endorse each paper. Same corpus, a different order for every researcher.

  1. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  2. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell)
  3. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells (Science Translational Medicine)
  4. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
  5. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (Journal of Clinical Oncology)
  6. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
  7. Neoantigens in cancer immunotherapy (Science)
  8. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity (Nature)
  9. The future of immune checkpoint therapy (Science)
  10. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity (Journal of Experimental Medicine)

Their papers